Icon

SAVAYSA (nda206316)- (EQ 15MG BASE,EQ 30MG BASE,EQ 60MG BASE)

EDOXABAN TOSYLATE DAIICHI SANKYO INC
EQ 15MG BASE,EQ 30MG BASE,EQ 60MG BASE
Yes No
2028-Mar-28 2020-Jan-08
None None
None No
SAVAYSA is a factor Xa inhibitor indicated: • To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.
0 1 0
Total Other Developers 6
Drugs with Suitability No
EQ 15MG BASE ** ** - - -
EQ 30MG BASE ** ** - - -
EQ 60MG BASE ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.